• Improved strategies for early case detection of leprosy, including context-specific community education materials to improve the perception and knowledge of leprosy and reduce stigma;

• More effective prevention of leprosy among contacts of new patients. The current regimen for post-exposure prophylaxis (PEP) of leprosy, single-dose rifampicin (SDR) reduces the risk of leprosy among contacts of new patients by 57%. We expect that three doses of the new PEP++ regimen, a combination of rifampicin/moxifloxacin for adults and rifampicin/clarithromycin for children, will be 80-90% effective;

• Identification of high-endemic clusters of leprosy through GIS-based mapping of current and recent cases;

• Blanket preventive chemotherapy in all villages and neighbourhoods where a cluster of leprosy patients has been identified.